Gilead purchase of novel cancer treatment raises cost issues again
A potential replay of the Sovaldi scandal is further complicated by the way the treatment is administered
Washington
GILEAD Sciences' acquisition of Kite Pharma has brought it back to a familiar - and contentious - dilemma: How much should a drugmaker charge for a novel drug that has the potential to cure a disease?
Back in 2013, Gilead was battered by public outrage when it priced its hepatitis C treatment Sovaldi at US$84,000, or US$1,000 a pill. The drug, which promised to rid patients of the viral disease in three months, also faced pushback from insurers and government plans that were expected to cover most of the cost.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
EU toughens rules on Chinese fashion retailer Shein
Shareholders raise questions over dividend payout, directors’ salaries at Best World AGM ahead of proposed privatisation
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand